Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Landos Biopharma Enters Strategic Research Collaboration with KU Leuven And University Hospitals Leuven To Further Characterize Effects Of NX-13 On Epithelial Cells

Author: Benzinga Newsdesk | September 14, 2023 08:03am

Recruitment, screening and randomization of patients continues, with top-line results on track for the fourth quarter of 2024. Landos expects to present results from this research collaboration at appropriate medical conferences in 2024.

Posted In: LABP


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist